List of Oligonucleotides Companies in Japan - 5

AnGes was founded In December 1999, with the aim of developing hepatocyte growth factor (HGF) gene therapy drugs which can help regenerate blood vessels. Originating from the word angiogenesis meaning the formation of new blood vessels in English, our corporate name AnGes encapsulates our desire to be an angel (ange in French) offering new drugs for patients with hard-to-treat and rare diseases. Both our founder and our employees are still motivated by this desire.

Axcelead Drug Discovery Partners, Inc. will combine scientific excellence, world-class IP protection and state-of-the art GLP accredited facilities and capabilities to deliver integrated end-to-end early discovery.

Luxna Biotech is a preclinical antisense drug development company based on proprietary modified nucleic acids, unique bridged structure (AmNA, scpBNA, GuNA) and modified DNA (5'-CP) can eliminate phosphorothioated in antisense and siRNA. Currently, better modifications are being discovered that are suitable for applications in neurological diseases that minimize neurotoxicity while maintaining knockdown efficacy in vivo by Gapmer. Based on these findings we developed excellent antisense (ASO) drug discovery platform called “LuxiAPTM” enable to wide therapeutic index for CNS ASO drug. We have several pharmaceutical collaborations and original ASO pipeline including ALS, Spinal cord injury and Hearing loss. We are looking for the partners not only for platform collaboration with pharmaceuticals and biotech but early-stage co-development alliance with our original pipeline.

Mochida Pharmaceutical - By aiming to become a comprehensive healthcare company, Mochida Pharmaceutical has made significant contributions in the field of medical care through its pharmaceuticals, healthcare products, and medical equipment businesses. Several years back, to improve the profitability, competitiveness value of all its divisions, Mochida Pharmaceutical split off the Medical Electronics and Equipment Division in 2003, the Healthcare Division in 2004 and the Pharmaceutical Manufacturing Division in 2005. Currently, the Group consists of Mochida Pharmaceutical and five consolidated subsidiaries. We at the Mochida Pharmaceutical Group remain committed as ever to contributing to peoples' health and well-being.

TAGCyx’s scientific team has established its proprietary Xenoligo® technology platform, allowing high functional oligonucletide drug discovery. The Xenoligo® platform utilizes genetic alphabet expansion by unnatural base-pairs to generate customized nucleic acid suited for therapeutic applications.